Trexquant Investment LP Purchases 76,184 Shares of CVRx, Inc. (NASDAQ:CVRX)

Trexquant Investment LP lifted its position in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 292.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 102,197 shares of the company's stock after buying an additional 76,184 shares during the quarter. Trexquant Investment LP owned about 0.42% of CVRx worth $1,295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of CVRX. Geode Capital Management LLC grew its stake in shares of CVRx by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 323,931 shares of the company's stock worth $4,105,000 after acquiring an additional 28,807 shares during the last quarter. Tradewinds LLC. bought a new position in shares of CVRx during the 4th quarter worth about $695,000. Norges Bank bought a new stake in shares of CVRx in the fourth quarter valued at about $1,411,000. JPMorgan Chase & Co. grew its position in CVRx by 10,520.1% during the fourth quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock worth $7,960,000 after buying an additional 622,370 shares in the last quarter. Finally, Emerald Advisers LLC raised its holdings in CVRx by 47.3% in the 4th quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock valued at $7,525,000 after acquiring an additional 190,844 shares in the last quarter. 75.27% of the stock is owned by institutional investors.

CVRx Price Performance

Shares of CVRX traded down $0.18 on Tuesday, hitting $6.35. The company's stock had a trading volume of 72,011 shares, compared to its average volume of 314,152. The company has a market capitalization of $165.43 million, a PE ratio of -2.36 and a beta of 1.34. CVRx, Inc. has a fifty-two week low of $5.87 and a fifty-two week high of $18.55. The company has a 50 day moving average price of $12.03 and a 200 day moving average price of $12.87. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. On average, research analysts anticipate that CVRx, Inc. will post -1.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CVRX shares. William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 14th. Piper Sandler lifted their target price on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Lake Street Capital cut their price target on shares of CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Canaccord Genuity Group decreased their price target on CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Finally, Craig Hallum upped their price target on CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.83.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.